Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, compounding
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatment Ozempic,
Pharmacists “desperation” by Novo Nordisk over semaglutide copycat block
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of Wegovy and Ozempic.
The Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster Drug
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical companies and compounders.
Ozempic maker Novo Nordisk wants the FDA to crack down on knockoff weight loss drugs
Ozempic maker Novo Nordisk (NVO) is asking the U.S. Food and Drug Administration (FDA) to prohibit compounding pharmacies from making off-brand versions of semaglutide, the active ingredient in its blockbuster weight loss and diabetes medications.
Novo asks FDA to bar compounders from making Ozempic copies
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable Difficulties for Compounding Lists."
Block production of compounded Ozempic, drug maker asks FDA
This week, Novo Nordisk, the Copenhagen, Denmark based pharmaceutical company, asked the US Food and Drug Administration (FDA) to add semaglutide to the agency’s Demonstrable Difficulties for Compounding (DDC) lists.
Novo Nordisk asks FDA to ban cheap copies of Wegovy, Ozempic, CNBC reports
Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks,
Novo seeks to block compounders' Ozempic copies
Novo Nordisk is pushing the FDA to block compounders from making copies of its Ozempic and Wegovy, saying the weight-loss treatments are too complex to safely replicate. Why it matters: It's the latest twist in the battle between pharma giants and compounders over the law that allows copies of patent-protected drugs amid shortages.
Drugmaker wants an end to Ozempic copies
FDA recalls thousands of antidepressant bottles due to cancer-causing chemical{beacon} Health Care Health Care The Big Story Novo
5h
on MSN
Ozempic May Reduce the Risk of Alzheimer’s. That’s Huge for Novo Nordisk.
Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.
BioSpace
5h
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...
9h
on MSN
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...
3d
Oral version of Novo diabetes drug protects heart health in large study
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback